Equity Profile

CPRX

Catalyst Pharmaceuticals, Inc.

Health CareBiotechnology$3.8B

Aug5Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will indicate how well the company is expanding its market presence and product adoption.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CPRX Q2-2026 Earnings Preview

Context

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases. With a market cap of $4 billion, it plays a crucial role in the healthcare sector, particularly in addressing unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.69%

Avg Stock Reaction

+0.67%

Last Quarter Recap

In Q1 2026, Catalyst Pharmaceuticals reported an EPS of $0.79, significantly exceeding expectations by 36.21%. The stock remained stable the following day, reflecting investor confidence.

Management Promises & Guidance

Continue to focus on expanding its product pipeline.
Maintain strong financial performance.
Explore new market opportunities for existing therapies.

Expectations

Wall Street Expectations

Overall expectations for Catalyst Pharmaceuticals are cautiously optimistic, given its strong track record of beating EPS estimates in previous quarters.

Bull Case

If the company continues its trend of strong earnings surprises, it could see significant stock price appreciation as investor confidence grows.

Bear Case

Conversely, any signs of slowing revenue growth or failure to meet earnings expectations could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of beating EPS estimates, this figure will be crucial in determining market sentiment post-earnings.

How is revenue growth tracking for the quarter?

Investors will closely watch revenue growth to gauge the company's market performance and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for continued strong earnings growth, given the company's recent performance and market position.

Supporting Evidence

Catalyst has consistently beaten EPS estimates, suggesting a trend of strong operational execution.

The options market is pricing in a significant move, indicating that investors expect volatility that may not align with consensus expectations.

Key Risk

If the EPS comes in below $0.58, it could undermine the bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce the company's growth story or signal potential challenges ahead.

Bull Confirmed If

An EPS of $0.80 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $0.58 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±5.68%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a relatively large move, suggesting that investors expect significant volatility around the earnings report.

Options are pricing ±5.7% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.4%

Calls (5K)P/C Ratio: 0.01Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.8%, with a raw directional average of +2.6% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Catalyst beats expectations, history suggests the stock could rise by around +0.67% on the following day, confirming strong investor confidence.

In-Line / Cautious

An in-line report may lead to muted reactions, with the stock potentially remaining stable as investors digest management commentary.

Miss

If the company misses expectations, history suggests a potential decline of around -1.94%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments.
2Management's commentary on market expansion strategies.
3Insights into competitive positioning within the biotechnology sector.
4Details on cost management and operational efficiencies.
5Guidance on future revenue projections.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Catalyst Pharmaceuticals, Inc. (CPRX) is a biotechnology company focused on developing and commercializing innovative therapies for rare diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will indicate how well the company is expanding its market presence and product adoption.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CPRX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+36.69%

Avg Stock Reaction

+0.67%

Last Quarter Recap

In Q1 2026, Catalyst Pharmaceuticals reported an EPS of $0.79, significantly exceeding expectations by 36.21%. The stock remained stable the following day, reflecting investor confidence.

Management Promises & Guidance

Continue to focus on expanding its product pipeline.
Maintain strong financial performance.
Explore new market opportunities for existing therapies.

Expectations

Wall Street Expectations

Overall expectations for Catalyst Pharmaceuticals are cautiously optimistic, given its strong track record of beating EPS estimates in previous quarters.

Bull Case

If the company continues its trend of strong earnings surprises, it could see significant stock price appreciation as investor confidence grows.

Bear Case

Conversely, any signs of slowing revenue growth or failure to meet earnings expectations could lead to a negative market reaction.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of beating EPS estimates, this figure will be crucial in determining market sentiment post-earnings.

How is revenue growth tracking for the quarter?

Investors will closely watch revenue growth to gauge the company's market performance and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the potential for continued strong earnings growth, given the company's recent performance and market position.

Supporting Evidence

Catalyst has consistently beaten EPS estimates, suggesting a trend of strong operational execution.

The options market is pricing in a significant move, indicating that investors expect volatility that may not align with consensus expectations.

Key Risk

If the EPS comes in below $0.58, it could undermine the bullish sentiment surrounding the stock.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it will either reinforce the company's growth story or signal potential challenges ahead.

Bull Confirmed If

An EPS of $0.80 or higher would confirm the bull case, indicating continued strong performance.

Bear Confirmed If

An EPS below $0.58 would raise concerns about the company's growth trajectory.

Pre-Earnings Positioning

Options Market

Implied Move

±5.68%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a relatively large move, suggesting that investors expect significant volatility around the earnings report.

Options are pricing ±5.7% while CPRX has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

30d HV

36.4%

Calls (5K)P/C Ratio: 0.01Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Catalyst beats expectations, history suggests the stock could rise by around +0.67% on the following day, confirming strong investor confidence.

In-Line / Cautious

An in-line report may lead to muted reactions, with the stock potentially remaining stable as investors digest management commentary.

Miss

If the company misses expectations, history suggests a potential decline of around -1.94%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments.
2Management's commentary on market expansion strategies.
3Insights into competitive positioning within the biotechnology sector.
4Details on cost management and operational efficiencies.
5Guidance on future revenue projections.